awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q33817568-3A123FC4-B3B0-43BB-A7AE-E2F2F790BE83
Q33817568-3A123FC4-B3B0-43BB-A7AE-E2F2F790BE83
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33817568-3A123FC4-B3B0-43BB-A7AE-E2F2F790BE83
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design
P2860
Q33817568-3A123FC4-B3B0-43BB-A7AE-E2F2F790BE83
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33817568-3A123FC4-B3B0-43BB-A7AE-E2F2F790BE83
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
cd6a3165e878a073d48720d7336410a6f5ff7879
P2860
Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.